Print this page    •   Back to Web version of article

HIV Point of Care Diagnostics Pipeline

By Polly Clayden

September 2011

Table of Contents


Access to appropriate care and treatment is dependent on first diagnosing HIV and then managing the infection both on and off treatment.

For anyone over 18 months old, an initial HIV diagnosis is usually made using a rapid antibody test - of which there is quite an array of choices that are cheap, accurate, and easy to use within decentralized care.

CD4 tests are recommended for staging and monitoring the disease prior to initiating antiretroviral treatment -- and for monitoring immune response to treatment, allowing opportunistic infection prophylaxis to be removed if higher CD4 counts are achieved -- and viral load tests once treatment is started.

Because of passive transplacental transfer of maternal antibodies that can persist for up to 18 months antibody tests cannot be used for the accurate diagnosis of infants. So virological testing needs to be performed to determine an infant's HIV status and enable immediate initiation of antiretroviral therapy (ART).


Although there are currently many options available for CD4 and virological testing, they are expensive and require sophisticated, centralized laboratories and trained technicians. To improve access to diagnostics in resource-limited settings and to make them affordable, they must be delivered as close as possible to the patient. A recent technical report from UNITAID describes a "diagnostic landscape" with high volume testing performed in centralized facilities ("super labs") where feasible, and, most importantly, a drive towards decentralized point of care (POC) testing in harder to reach populations.1

This chapter looks at the latter and describes promising POC technologies in the pipeline for CD4, viral load and early infant diagnosis (EID). These tests may be commercially available within the next couple of years. Many of the test sponsors appear to believe that their products will launch commercially next year. If their predictions come true then 2012 will be a bumper year for HIV POC diagnostics. The authors cannot guarantee that this bonanza will occur in 2012.

Diagnostic Tests


CD4 tests determine the number or percentage of CD4 T cells in a mm3 of blood.

Flow cytometry is the gold standard technique for CD4 testing. It is a technique for counting CD4 cells by suspending them in a stream of liquid and passing them by an electronic detector.

The machines used to perform these tests are big and expensive, use complex systems of lenses, lasers and electronics, and require an uninterrupted supply of electricity and highly trained technicians.


Polymerase Chain Reaction (PCR) tests detect the genetic material of HIV (rather than antibodies). Extracting and amplifying the genetic material of HIV and then detecting it with a PCR test is called nucleic-acid amplification testing or NAT. NAT tests are either, RNA PCR (viral load) or DNA PCR (which detects HIV when integrated into the host cell's DNA) tests.

DNA-PCR testing is most commonly used for EID. Although DNA-PCR has been used in resource-limited settings, its long turnaround time contributes to infant loss-to-follow-up and loss of benefit of immediate initiation of treatment. These tests do not provide measurements like RNA-PCR, but just detect the presence of the virus and give a "yes" or "no". Currently, no POC DNA-PCR tests are available for infants.


The p24 protein is the antigen that most commonly provokes an antibody response to HIV. Early in HIV infection, p24 is produced in quantity and can be detected in the blood. It falls to low levels as the infection becomes established.

p24 antigen tests are not usually used for general HIV diagnosis, as they have a very low sensitivity and they only work before antibodies are produced in the period immediately after HIV infection. But p24 tests could be useful for EID.

In order for a diagnostic test to be useful within a decentralized setting it should meet the WHO ASSURED criteria for the ideal rapid test, which is as follows:

A = affordable
S = sensitive
S = specific
U = user friendly (simple to perform in a few steps with minimal training)
R = robust and rapid (results available in less than 30 minutes)
E = equipment free
D = deliverable to those who need the test

CD4 Tests

The CD4 Initiative, based at Imperial College in London, was set up in 2005 to develop simple, instrument-free CD4 point of care tests designed specifically for rural areas in resource-limited settings.2

They began with a target product profile with a set of specifications that elaborate on the ASSURED criteria.

In partnership with Zyomyx they have developed a fully quantative CD4 counter, that can be read visually without an electronic reader, much like a thermometer. It consists of a disposable cartridge with a mechanical spinner that requires no power supply. The test can measure an absolute CD4 count without complex instruments. Clinical trials are expected in 2011. If the results are positive, the test could begin to become available by 2012, according to Zyomyx.3

The Burnet Institute -- who also worked on their prototype within the CD4 Initiative -- is continuing to develop a rapid CD4 test in collaboration with the Rush University Medical Center and Duke University.4

This test is semi-quantative and will give a read out showing whether someone's CD4 count is above or below a predetermined threshold -- e.g., 350 cells/mm3. The user then can make a treat/don't treat decision. Burnet is developing a reader for the device in collaboration with Axxin Ltd.

Clinical trials are planned in 2011 in the United States and Malawi. The further development and the launch of this test will depend on trial results and project funding.

Daktari Diagnostics is in late stage development of a portable CD4 cell counter. The device is a portable battery run instrument. Each CD4 test consists of a disposable plastic card, which is inserted into the instrument. The test measures absolute CD4 count.5

Validation studies in four African countries are expected to be underway this year. Follow-on studies in additional countries are also planned. The commercial launch is expected at the end of 2011.

MBio Diagnostics is developing a system that uses disposable cartridges and a simple reader instrument. It provides an absolute CD4 count.6

Field-testing in southern Africa is scheduled for later this year.

Table 1: CD4 Point of Care Test Pipeline
TestTurnaround Time/CapacitySample NeededCost Test/Instrument*PowerEnvironmentTraining (Layperson)
Zyomyx CD4 counter10 minutes
40 samples per day
100 uL finger stick blood$6-7
NoneTBDLess than 30 minutes
Burnet Institute CD4 counter20 minutes
8-10 tests per hour (running cartridges in parallel)
10 μL finger stick blood; can also use venous bloodTBDBatteryTBDLess than 120 minutes
DaktariTM CD4 Counter8 minutes
40-50 samples per day
20 μL finger stick blood applied to cartridge$8
AC, on board long life rechargeable batteryTemperature 4O to 370Less than 90 minutes
MBio CD4 system20 minutes
8-10 tests per hour
10 μL finger stick blood; can also use venous bloodTBDBatteryTBDLess than 90 minutes
* Estimated cost.

Viral Load

The SAMBA (simple amplification based assay), is currently being developed by the Diagnostics Development Unit at the University of Cambridge.7

They are developing two tests, a semi quantative test for monitoring ART and a qualitative test for EID. The tests use isothermal amplification and visual detection by dipstick. SAMBA is being field tested by MSF in Malawi.8

The Liat TM Analyser, manufactured by IQuum, POC HIV assay is a real time, battery operated, small, portable, PCR kit. Blood is collected in a tube and inserted into the analyzer. Results are quantitative.

Clinical trials are scheduled for 2011 with the potential for launch in 2012.9

Alere NAT system is a generic platform designed to detect various nucleic acids. The first test -- anticipated to be commercially launched next year -- is a real time detection method for measuring quantative HIV RNA. The sample -- which can be from finger-stick, whole blood, or plasma -- is applied directly onto the disposable cartridge, which is processed by a compact, battery driven instrument.10

Table 2: Viral Load Point of Care Test Pipeline
TestTurnaround Time/CapacitySample NeededCost Test/Instrument*PowerEnvironmentTraining (Layperson)
SAMBA60 minutes
4 samples per run
200mL plasma or 100 μL bloodTBD
$2500 to $5000
AC or batteryN/AMinimal
LiatTM Analyser30 to 55 minutes
8 to 15 samples per day (depending on limit of detection)
200mL plasma or 10-50 μL of finger stick bloodTBDAC or batteryOperating Temperature 15° to 30° C (59° to 86° F)One hour
Alere 0 to 60 minutes25 μL finger stickTBDOn board rechargeable batteryOperating Temperature: 15° to 40° C (59° to 104° F)
Humidity: <90% relative humidity
Maximum altitude: N/A (permissible atmospheric pressure: 850 to 1100 hPa)
Less than 90 minutes
* Estimated cost.

Early Infant Diagnosis

Virological testing or ultrasensitive p24 antigen testing should be used for EID. It is possible to use qualitative HIV RNA assays, as described above, as an alternative to HIV DNA. The SAMBA system is developing a test especially for this purpose.

North Western Global Health Foundation (NWGHF) is developing an HIV DNA-PCR test which is on hold -- is not yet ready for field-testing -- while the group focuses on a POC p24 test.11

Both Micronics and BioHelix have DNA tests which appear to be in the proof of concept stage and are not ready for field-testing yet either.

The NWGHF p24 antigen rapid test consists of a plasma separator, reaction tube, reaction buffer, and rapid test strip. It is small, battery operated, and expected to be inexpensive. It has demonstrated about 95% sensitivity and 99% specificity.12

Clinical and field trials are expected to start this year and it should be available in 2012.

Table 3: p24 Test for EID Pipeline
TestTurnaround Time/CapacitySample NeededCost Test/Instrument*PowerEnvironmentTraining (Layperson)
NWGF p24 lateral flow assay30 minutes
16 samples per day
75mL heel stick blood$10
* Estimated cost.


  1. Murtagh MM. HIV/AIDS Diagnostic Landscape. UNITAID Technical Report. May 2011
  2. CD4 Initiative. Imperial College, London.
  3. Zyomyx.
  4. Burnet Institute, Centre for Virology.
  5. Daktari Inc.
  6. MBio Diagnostics.
  7. University of Cambridge. Department of Haematology. Diagnostics Development Unit.
  8. Malawi: SAMBA trial -- Médecins Sans Frontières (MSF).
  9. IQuum Products.
  10. Alere.
  11. Northwestern Global Health Foundation.
  12. McCormick. Northwestern Engineering. Centre for Innovation in Global Health Technologies. p24 Antigen Rapid Test for Pediatric HIV Diagnosis.

Additional Sources

Murtagh MM. HIV/AIDS Diagnostic Landscape. UNITAID Technical Report. May 2011.

Clayden P. Early infant diagnosis. HIV Treatment Bulletin. October 2010.

This article was provided by Treatment Action Group and HIV i-Base. It is a part of the publication 2011 Pipeline Report. You can find this article online by typing this address into your Web browser:

General Disclaimer: is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.